hotspot -WSS

hotspot

author：explore 2025-09-30 00:45:41 - browse：9612

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Novo Nordisk touts Wegovy study, but still struggling with supply

leisure time

knowledge

WSS

Judge sides with young activists in first

HHS names first

Patients, digital health players weigh in on FTC's data privacy plan

YouTube cracks down on misinformation on cancer treatment

DeSantis can now import cheaper drugs. But will Biden get credit?

The SUPPORT Act is critical to fighting the opioid crisis

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Aspartame and sugar

Sports medicine is finally prioritizing gender equality

The SUPPORT Act is critical to fighting the opioid crisis

Dobbs anniversary: the lost opportunity of abortion as health care

BMS, looking to build heart drug business, turns to AI for diagnosis

Medicare proposal to cover medical devices draws a mixed reaction

After Optum profits sink, UnitedHealth makes changes

At least 13 dead in Texas as scorching temps continue

Surge in Apellis stock fueled by confidence in safety of its eye drug

knowledge

Heart disease and mental health: A look at cardiac psychology

Risky weight loss products often used by teens globally, per study

Judge sides with young activists in first

Hospitals are dialing back on venture capital investing

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

New Medicare drug pricing powers could soon be upended in court

leisure time

hotspot

knowledge

leisure time